Free Trial
NASDAQ:NMTC

NeuroOne Medical Technologies (NMTC) Stock Price, News & Analysis

NeuroOne Medical Technologies logo
$0.68 0.00 (-0.25%)
As of 06/30/2025 04:00 PM Eastern

About NeuroOne Medical Technologies Stock (NASDAQ:NMTC)

Key Stats

Today's Range
$0.67
$0.73
50-Day Range
$0.54
$0.73
52-Week Range
$0.40
$1.39
Volume
202,673 shs
Average Volume
186,252 shs
Market Capitalization
$33.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.45
Consensus Rating
Buy

Company Overview

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

NeuroOne Medical Technologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

NMTC MarketRank™: 

NeuroOne Medical Technologies scored higher than 61% of companies evaluated by MarketBeat, and ranked 416th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NeuroOne Medical Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    NeuroOne Medical Technologies has only been the subject of 1 research reports in the past 90 days.

  • Read more about NeuroOne Medical Technologies' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NeuroOne Medical Technologies is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NeuroOne Medical Technologies is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NeuroOne Medical Technologies has a P/B Ratio of 22.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about NeuroOne Medical Technologies' valuation and earnings.
  • Percentage of Shares Shorted

    0.42% of the float of NeuroOne Medical Technologies has been sold short.
  • Short Interest Ratio / Days to Cover

    NeuroOne Medical Technologies has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeuroOne Medical Technologies has recently decreased by 8.13%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    NeuroOne Medical Technologies does not currently pay a dividend.

  • Dividend Growth

    NeuroOne Medical Technologies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.42% of the float of NeuroOne Medical Technologies has been sold short.
  • Short Interest Ratio / Days to Cover

    NeuroOne Medical Technologies has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeuroOne Medical Technologies has recently decreased by 8.13%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    NeuroOne Medical Technologies has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for NeuroOne Medical Technologies this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, NeuroOne Medical Technologies insiders have bought 2,593.48% more of their company's stock than they have sold. Specifically, they have bought $150,000.00 in company stock and sold $5,569.00 in company stock.

  • Percentage Held by Insiders

    Only 8.90% of the stock of NeuroOne Medical Technologies is held by insiders.

  • Percentage Held by Institutions

    Only 16.07% of the stock of NeuroOne Medical Technologies is held by institutions.

  • Read more about NeuroOne Medical Technologies' insider trading history.
Receive NMTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroOne Medical Technologies and its competitors with MarketBeat's FREE daily newsletter.

NMTC Stock News Headlines

Gold Shock (insane new prediction)
World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "financially stressed." Over 2.2 million Americans saw their credit score fall 100 points from late payments. And everything from Red Lobster to Walmart to CVS is closing stores. What happens next will be even worse, but could hand savvy gold investors huge gains. There IS a right way to buy gold.
See More Headlines

NMTC Stock Analysis - Frequently Asked Questions

NeuroOne Medical Technologies' stock was trading at $0.8259 at the start of the year. Since then, NMTC stock has decreased by 17.9% and is now trading at $0.6783.
View the best growth stocks for 2025 here
.

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) posted its earnings results on Tuesday, May, 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.02. The business had revenue of $1.39 billion for the quarter, compared to analysts' expectations of $1.27 billion. NeuroOne Medical Technologies had a negative trailing twelve-month return on equity of 334.64% and a negative net margin of 75.41%.
Read the conference call transcript
.

Shares of NMTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroOne Medical Technologies investors own include Schwab US Large-Cap ETF (SCHX), NVIDIA (NVDA), Advanced Micro Devices (AMD), NIO (NIO), Ford Motor (F), Meta Platforms (META) and Plug Power (PLUG).

Company Calendar

Last Earnings
5/13/2025
Today
6/30/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Services
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:NMTC
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.45
High Stock Price Target
$1.45
Low Stock Price Target
$1.45
Potential Upside/Downside
+113.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.32 million
Pretax Margin
-75.40%

Debt

Sales & Book Value

Annual Sales
$3.45 million
Price / Cash Flow
N/A
Book Value
$0.03 per share
Price / Book
22.61

Miscellaneous

Free Float
45,384,000
Market Cap
$33.79 million
Optionable
Optionable
Beta
0.63
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:NMTC) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners